AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03875183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INL1
Description: Capsules
Study NCT03875183 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules
Study NCT02143947 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Maximal Arch Subtalar Stabilization
Description: Custom made semi-rigid thermoplastic heel cup extending to the base of the metatarsals with a full foot length 3.0mm thick EVA and ultra-suede top cover
Study NCT02143947 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Full Contact Orthosis
Description: The Full Contact orthosis is constructed from a 5/32 blue polypropylene with posting material comprised of white polypropylene.
Study NCT01156961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: 90 mg/m2 iv days 1, 8 and 15 of every 28-day cycle or 175 mg/m2 iv day 1 of each 21-day cycle
Study NCT04633512 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ActivSight
Description: Use of ActivSight in patients undergoing laparoscopic or robot assisted intestinal anastomoses and patients undergoing laparoscopic or robot assisted cholecystectomy.
Study NCT02393950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ODM-106
Description: Single oral escalating doses of ODM-106 will be administered. Each subject will participate in 4 study periods and will therefore receive 3 single doses of ODM-106 and one single dose of placebo.
Study NCT02393950 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single oral escalating doses of ODM-106 will be administered. Each subject will participate in 4 study periods and will therefore receive 3 single doses of ODM-106 and one single dose of placebo.
Study NCT03610126 — intervention group
Intervention type: PROCEDURE
Intervention: volume controlled ventilation
Description: the patients will be ventilated by volume controlled ventilation after insertion of the BASKA laryngeal mask airway
Study NCT03610126 — intervention group
Intervention type: PROCEDURE
Intervention: pressure controlled ventilation
Description: the patients will be ventilated by pressure controlled ventilation after insertion of the BASKA laryngeal mask airway
Study NCT00941330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: 25 mg daily by mouth for 6 to 12 months.
Study NCT00941330 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel (75 mg/m²) into a vein once every 3 weeks for 6 cycles (6 times in about 24 weeks).
Study NCT04391673 — intervention group
Intervention type: BEHAVIORAL
Intervention: Vestibular rehabilitation
Description: Vestibular rehabilitation (treatment as usual).
Study NCT00941330 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytoxan
Description: Cytoxan (600 mg/m²) into a vein once every 3 weeks for 6 cycles (6 times in about 24 weeks).
Study NCT01944904 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Sugar Pill
Description: The placebo is identical in appearance to the XOS and contains 505mg maltodextrin
Study NCT01944904 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: XOS 2.8
Description: 2.8g XOS is white or off-white crystalline substance and contains 500mg XOS 70P and 20mg maltodextrin
Study NCT03606330 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac imaging tests
Description: * 2D transthoracic echocardiography~* 128-multislice CT coronary angiography with the evaluation of: epicardial fat volume, plaque burden, total and local calcium score, markers for lesion severity; morphological plaque characteristics; plaque components evaluated via volumetric and planimetric units; markers of plaque vulnerability (necrotic core, low attenuation plaque, spotty calcification, napkin ring sign, positive remodeling).~* Shear stress evaluation via computational fluid dynamics.~* Intracoronary imaging techniques: IVUS and OCT.
Study NCT03606330 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Venous blood sample collection
Description: Venous blood sample collection during the acute coronary event for evaluation of serum levels of hsCRP, IL-6, matrixmetalloproteases MMP9, Adhesion molecules (VCAM, ICAM), alfa tumour necrosis factor, hs-cTnI, NTproBNP
Study NCT02023970 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Patients receiving animal-derived bioprosthetic heart valves.
Study NCT02023970 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Echocardiography (1)
Study NCT02023970 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Echocardiography (2)
Study NCT02023970 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Echocardiography (3)
Study NCT02023970 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Blood sample (1)
Study NCT02023970 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Blood sample (2)
Study NCT02023970 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Blood sample (3)
Study NCT01167725 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: bevacizumab
Description: Given IV
Study NCT01167725 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV
Study NCT01167725 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: cetuximab
Description: Given IV
Study NCT01167725 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Given IV
Study NCT01167725 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFIRI regimen
Description: Given IV
Study NCT01167725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI regimen
Description: Given IV
Study NCT01167725 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX regimen
Description: Given IV
Study NCT01167725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX regimen
Description: Given IV
Study NCT01167725 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: capecitabine
Description: Given IV
Study NCT01167725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Given IV
Study NCT01167725 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluorouracil
Description: Given IV
Study NCT01167725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV
Study NCT01167725 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: irinotecan hydrochloride
Description: Given IV
Study NCT03300349 — intervention group
Intervention type: OTHER
Intervention: Fulfillment of a preventive programme
Description: Information about risk factors for breast cancer-related lymphedema and home-based exercise programme for shoulder
Study NCT03300349 — intervention group
Intervention type: OTHER
Intervention: No fulfillment of a preventive programme
Description: No fulfillment of the preventive programme: Information about risk factors for breast cancer-related lymphedema and home-based exercise programme for shoulder
Study NCT01167725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: Given IV
Study NCT01167725 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: leucovorin calcium
Description: Given IV
Study NCT01167725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV
Study NCT01167725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mitomycin C
Description: Given intraperitoneally
Study NCT02846181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-SK-1405
Study NCT01167725 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxaliplatin
Description: Given IV
Study NCT01167725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV
Study NCT01167725 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Patients undergo cytoreductive surgery
Study NCT03621254 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: [LO-LONG]
Description: Both interventions are different modalities of FES-evoked leg exercise, three-four times per week for 6-8 weeks (24 therapy sessions). The comparator intervention (\[LO-LONG\]) uses 20-40 min (patient state of fitness dependent) of continuous leg exercise of lower intensity.
Study NCT03621254 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: [HI-SHORT
Description: One intervention (\[HI-SHORT\]) uses a variety of leg exercise interval training of higher intensity for 10 x 2-min intervals.
Study NCT04068831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: 1 mg talazoparib daily
Study NCT04068831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: 800 mg avelumab every 2 weeks
Study NCT03624465 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Levita Magnetic Surgical System
Description: Device for use as a surgical tool.
Study NCT04339192 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimally Invasive Tricuspid Surgery
Description: minimally invasive tricuspid surgery including endoscopy-assist right minithoracotomy, vacuum-assist single femoral venous drainage without dissecting or snaring vena cava, direct right atriotomy through pericardium and the beating-heart technique.
Study NCT05598216 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: no intervention, Serum LDL cholesterol calculation
Description: The serum LDL cholesterol concentrations will be calculated using at least three different equations (Friedewald, Sampson, Martin-Hopkins)
Study NCT00556933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rabbit anti-thymocyte globulin - single dose
Description: A single 6 mg/kg dose of rATG administered intravenously over 24 hours, beginning before kidney transplantation. Administration of the drug is begun as early as practical, usually after general anesthesia has been established but before surgery has started. The rATG is therefore administered for about two hours before blood flow is restored to the kidney undergoing transplantation.
Study NCT04406142 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VISUAL
Description: thin catheter insertion between vocal cords under direct specially adapted videolaryngoscopy
Study NCT02137239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymoglobulin
Study NCT02137239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belatacept
Study NCT01880723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol
Description: 2.5 mg diluted in 3mL normal saline nebulized using a Power Neb2 nebulizer
Study NCT01880723 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo saline
Description: nebulized 3mL normal saline) using a Power Neb2 nebulizer
Study NCT02137239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil(MMF)
Study NCT02137239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Study NCT02137239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus(EVL)
Study NCT03129828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib and Bortezomib + R-CHOP
Description: A pre-phase therapy with Prednisone 100 mg p.o. is mandatory from d-4 until d0. Patients receive 6 cycles of a combined immunochemotherapy with the anti-CD20 antibody Rituximab (375 mg/m2 d0 or d1) together with 6 cycles of a chemotherapy consisting of Cyclophosphamide (750 mg/m2 d1), Doxorubicin (50 mg/m2 d1), Vincristine 1 mg absolute d1), Prednisone (100 mg absolute p.o. d1-5) and Bortezomib s.c. (1.3 mg/m2 C1 on d3 and 8, other cycles d1 and d8), in 21-day intervals and Ibrutinib 560 mg p.o. for individuals \< 65 years and 420 mg p.o. for individuals ≥ 65 years (from d6 of C1 until d21 of C6), followed by two additional 3-week cycles of Rituximab (375 mg/m2).
Study NCT04505410 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A plant based high fiber diet that mimics fasting (FMD) plus advanced therapy
Description: Patients will do two 5-day cycles of a fasting mimicking diet. They will start the first diet cycle 1 week after initiating a new advanced therapy: Tofacitinib and Upadacitinib (JAK inhibitors), Infliximab (anti-TNF), Ustekinumab or Risankizumab (IL-23 inhibitors).
Study NCT04505410 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Advanced therapy only without dietary intervention
Description: Patients in this group will start an advanced therapy and follow a diet solely based on dietary tolerance: new advanced therapy: Tofacitinib and Upadacitinib (JAK inhibitors), Infliximab (anti-TNF), Ustekinumab or Risankizumab (IL-23 inhibitors).
Study NCT02137239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus(TAC)
Study NCT00760630 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FFR/CFR and IVUS
Description: All patients with clinical indication for cardiac cath will have FFR and IVUS
Study NCT00556933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: Patients are switched approximately 6 months after kidney transplantation from maintenance immunosuppression with tacrolimus and sirolimus to maintenance with mycophenolate mofetil and sirolimus. The drug is administered orally, taken daily, with dose adjusted in proportion to measured blood levels, and is required indefinitely to prevent rejection of the transplanted kidney.
Study NCT00556933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rabbit anti-thymocyte globulin - 4 doses
Description: 6 mg/kg rabbit anti-thymocyte globulin delivered in 4 doses of 1.5 mg/kg each, the first administered at the time of kidney transplantation. Subsequent doses are administered on days 2, 4, and 6.
Study NCT00556933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sirolimus
Description: Oral maintenance immunosuppressant administered daily, dose adjusted according to measured serum trough levels, continued indefinitely to prevent kidney rejection
Study NCT00556933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: Oral maintenance immunosuppressant, taken daily, dose adjusted to maintain target blood trough levels, required indefinitely to prevent kidney rejection.
Study NCT03684707 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin Hcl 500Mg 24Hr Sa Tab
Description: Glucophage 500 mg once daily
Study NCT03684707 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: starch tablet
Description: starch tablets
Study NCT04604171 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Action Observation Training
Description: Action Observation Training (AOT) is composed, according to Franceschini et al. (2012), by 20 different videos of daily activities (actions) carried out with the upper limbs. Patients underwent only one task per day for 20 sessions, starting from the easiest. Each action (unimanual or bimanual) is observed from a first-person perspective. Actors in the videos are young non-disabled people, either men or women. Patients are asked to carefully observe the videos, in order to prepare themselves to imitate the presented actions, while the therapist consistently holds the patient's attention with verbal feedback. At the end of each sequence, the therapist prompts the patient to perform the same movement with the paretic upper limb over a time period of 2 minutes, providing verbal instructions or help, if needed. Each session lasts about 30 minutes (3 min of sequence observation and 2 min of action performance for 3 motor sequences repeated twice).
Study NCT04604171 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Task Oriented Training
Description: In Task Oriented Training patients performed functional activities with the upper limbs, using the same objects for AOT, in both unimanual and bimanual modalities, without watching the video beforehand. The therapist just provided for verbal instructions and feedback, avoiding demonstrative or imitative indications. The therapist could passively support the movement if patients were completely unable to perform the actions. When necessary, the therapists could also actively facilitate the upper limb movement if patients were unable to correctly perform the actions. Based on the patient's level of motor ability and progress, the levels of movement and task difficulty could be adjusted accordingly. Patients underwent one task per day for 20 sessions. Each session lasted about 30 minutes.
Study NCT04604171 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conventional Treatment
Description: Conventional treatment consists of a range of different patient-tailored interventions, selected by the therapist on the basis of the functional level of the patient. Treatment sessions include training for transfers, mobility, walking up and down steps, balance tasks and tailored functional tasks for the upper limbs (unimanual and bimanual). Moreover, it is also provided for joint and soft tissue mobilization, specific sensory stimulation, exercises to increase strength, both for lower and upper limbs. Each session lasted about 60 minutes.
Study NCT04604171 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Treatment
Description: Conventional treatment consists of a range of different patient-tailored interventions, selected by the therapist on the basis of the functional level of the patient. Treatment sessions include training for transfers, mobility, walking up and down steps, balance tasks and tailored functional tasks for the upper limbs (unimanual and bimanual). Moreover, it is also provided for joint and soft tissue mobilization, specific sensory stimulation, exercises to increase strength, both for lower and upper limbs. Each session lasted about 60 minutes.
Study NCT02505750 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3D conformal EBRT
Description: External Beam Radiation Therapy
Study NCT02505750 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 3D conformal EBRT
Description: External Beam Radiation Therapy
Study NCT02505750 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contact X-ray brachytherapy 50 kV
Study NCT04287868 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PDS0101
Description: PDS0101 will be administered on Day (D)1, D15, D29 followed by booster vaccines every 4 weeks for up to a year. Subcutaneous 1.0mL (2.4mg of total peptide and 3 mg of R-DOTAP) injection.
Study NCT04287868 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: M7824
Description: M7824 will be administered at a flat dose of 1,200 mg intravenous (IV) (over 1 hour) once every 2 weeks.
Study NCT04287868 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NHS-IL12
Description: NHS-IL12 will be administered at as dose of potentially de-escalating doses by subcutaneous (SC) injection every 4 weeks.
Study NCT04046549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belatacept
Description: Protocol versions 1 through 4: Belatacept 10 mg/kg by intravenous (IV) infusion on post-op Day 1, repeated on post-op Day 3 or 4 (timing is at investigator's discretion), and at the end of Weeks 2, 4, 8 and 12; then 5 mg/kg IV every 4 weeks from Week 16 to Week 48.
Study NCT04046549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIB4920
Description: Protocol versions 1 and 2: VIB4920 1500 mg by IV infusion on post-op Days 1 and 14, and at the end of Weeks 4, 6, 8 and 10; then 1500 mg every 4 weeks from Week 12 to Week 48.~Protocol versions 3 and 4: VIB4920 1500 mg by IV infusion on post-op Days 1, repeated on post-op Day 3 or 4 (timing is at investigator's discretion), Week 2, and at the end of Weeks 4, 6, 8, and 10; then 1500 mg every 4 weeks from Week 12 to Week 48.
Study NCT04046549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymoglobulin
Description: Protocol versions 1 and 2: Thymoglobulin 3.0 mg/kg by intravenous (IV) infusion prior to reperfusion of the allograft on the day of transplantation surgery (Day 0) (1 dose).~Protocol versions 3 and 4: Thymoglobulin 1.5 mg/kg by intravenous infusion prior to reperfusion of the allograft on the day of transplantation surgery (Day 0), prior to VIB4920+belatacept infusion on post-op Day 1, on post-op Day 2, and prior to VIB4920+belatacept infusion on post-op Day 3 or 4.
Study NCT04046549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Protocol versions 1 and 2: Methylprednisolone by IV infusion (500, 250, 125 and 60 mg on Days 0, 1, 2 and 3, respectively) followed by oral administration of prednisone 30 mg per day on Days 4, 5, and 6.~Protocol versions 3 and 4: Methylprednisolone by IV infusion (500, 250, 125 and 60 mg on Days 0, 1, 2 and 3, respectively) followed by oral administration of prednisone 30 mg per day on Days 4, 5, 6 and 7. Participants may be tapered to at least 20 mg per day on Day 8, to at least 10 mg per day on Day 15, and to at least 5 mg per day on Day 22. Discontinuation of prednisone following the post-op Day 28 visit.
Study NCT03493542 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V501
Description: 0.5 mL intramuscular injection in the deltoid muscle at Day 1, Month 2, and Month 6
Study NCT03493542 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: V501
Description: 0.5 mL intramuscular injection in the deltoid muscle at Day 1, Month 2, and Month 6
Study NCT02505750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Study NCT02505750 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine